Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech has maintained a robust financial position, ending the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, which supports its ongoing research and development initiatives. The incremental positive news surrounding its BNT323 drug candidate for breast cancer indicates a promising outlook as it enters global Phase 3 clinical trials, potentially expanding its oncology pipeline. Moreover, the company has made headway with its LP.8.1-adapted monovalent COVID-19 vaccine, showing improved immune responses against various circulating SARS-CoV-2 sublineages, underscoring its continued relevance in the vaccine market alongside its ambitious therapeutic pursuits.

Bears say

BioNTech faces numerous risks that contribute to a negative outlook, including potential negative clinical data from several of its cancer therapeutics and slower-than-expected market uptake of its products. The company reported a net loss per diluted share of €0.12 in the third quarter of 2025, with projected full-year losses reaching €3.99 per share, signaling financial difficulties. Additionally, investor focus may remain on the challenges posed by a shifting landscape in the COVID-19 vaccine market, particularly due to regulatory changes in the U.S., overshadowing BioNTech's oncology pipeline developments.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.